⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CCCC News
C4 Therapeutics, Inc.
C4 Therapeutics to Participate in Upcoming March Conferences
globenewswire.com
CCCC
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
globenewswire.com
CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CCCC
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CCCC
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
globenewswire.com
CCCC
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
CCCC
Precision Oncology Approaches Drive $312B Market Transformation
prnewswire.com
GTBP
NRIX
GRAL
CCCC
PFE
GTBP
NRIX
GRAL
CCCC
PFE
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
globenewswire.com
CCCC
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
globenewswire.com
CCCC